Biospecifics Technologies (BSTC)
Biospecifics Technologies Revenue Growth: 39.30%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BSTC Revenue Growth Rankings
| Overall | 89th percentile | 457 of 4358 |
| Sector | 81st percentile | 85 of 456 in Healthcare |
| Industry | 66th percentile | 42 of 126 in Biotechnology |
BSTC Revenue Growth Range, Past 5 Years
| Minimum | -89.57% | Dec 2009 |
| Maximum | 1644% | Dec 2008 |
| Average | 163.2% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these BSTC related companies
BSTC News
BioSpecifics Technologies Corp. Reports First Quarter 2012 Financial Results
May 10, 4:00PM PR Newswire
May 10, 4:00PM PR Newswire
BioSpecifics Technologies Corp Announces Initiation of Phase II Trial for Canine Lipomas
May 07, 7:33AM Benzinga
May 07, 7:33AM Benzinga
BioSpecifics Technologies Corp. Announces Initiation of Phase II Trial for Canine Lipomas
May 07, 7:30AM PR Newswire
May 07, 7:30AM PR Newswire
$BSTC filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3aVw
about 28 days ago by MarketBrief
about 28 days ago by MarketBrief
MKM Starts BioSpecifics Technologies (BSTC) at Buy, Sets $26.50 Target
Apr 05, 12:26PM Street Insider
Apr 05, 12:26PM Street Insider
UPDATE: Stifel Nicolaus Initiates Buy, $29 Target on BioSpecifics Technologies
Mar 15, 12:03PM Benzinga
Mar 15, 12:03PM Benzinga
Listen to $BSTC Q4 2011 earnings call - live at 08:30 AM, ondemand after - http://stks.co/2kxD
about 80 days ago by earningscast
about 80 days ago by earningscast
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2011 Financial Results
Mar 09, 7:30AM PR Newswire
Mar 09, 7:30AM PR Newswire
BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
Dec 09, 8:00AM PR Newswire
Dec 09, 8:00AM PR Newswire
BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Nov 09, 8:00AM PR Newswire
Nov 09, 8:00AM PR Newswire
BioSpecifics Technologies Corp. Reports Third Quarter 2011 Financial Results
Nov 08, 7:30AM PR Newswire
Nov 08, 7:30AM PR Newswire
$BSTC $23.79 Geller Matthew director S 12,300 @ $24.01 amnt $295,325 proc'd $2,755 5/23/2011
about 370 days ago by canarionyc
about 370 days ago by canarionyc
RT @HCPG http://nyti.ms/cJKu4Q &lt;--Um, did you just put $AUXL & $BSTC on your watch list like I did?
about 804 days ago by RAEckart
about 804 days ago by RAEckart
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BSTC | 16.39 | -0.01 | -0.06% | 103.91M |
| BSRR | 9.01 | +0.06 | +0.67% | 127.04M |
| BSQR | 2.65 | -0.02 | -0.75% | 28.86M |
| BSP | 8.43 | +0.00 | +0.00% | |
| BSI | 2.555 | +0.01 | +0.59% | 168.60M |
| CB | 71.75 | -0.35 | -0.49% | 19.40B |
| CAW | 4.06 | +0.06 | +1.50% | 28.62M |
| CAVM | 23.77 | -0.09 | -0.38% | 1.174B |
| CATY | 16.68 | -0.18 | -1.07% | 1.312B |
| CATO | 29.33 | +0.53 | +1.84% | 804.23M |
